Shots: The P-III ALEX study involves assessing of Alecensa vs crizotinib in 303 treatment-naïve patients in a ratio (1:1) with ALK+ NSCLC whose tumors were characterized as ALK+ by the […]readmore
Tags : Alecensa
Shots: The approval is based on P-II STARTRK-2 study assessing the efficacy of Rozyltrek in ROS1 fusion-positive NSCLC cohort while the safety is evaluated in two P-I studies (STARTRK-1 study […]readmore
Shots: Alecensa approval in china is after 8 & 9 mos post EMA and US FDA approvals, Alecensa is now approved in over 57 countries The approval is based on […]readmore